Toronto Western Hospital represents the first Canadian site for San Diego-based InVivo Therapeutics’ cervical spinal cord injury study.
Here are seven things to know:
1. Toronto Western Hospital’s Research Ethics Board approved patient enrollment in the study on March 30, 2017.
2. Michael Fehlings, MD, PhD, will serve as the site’s principal investigator for the cervical spinal cord injury study.
3. Dr. Fehlings serves as the director of the spinal program at Toronto Western Hospital’s Krembil Neuroscience Centre as well as a surgery professor and member of the Institute of Medical Sciences School of Graduate Studies.
4. He also serves as a scholar in the McLaughlin Centre of Molecular Medicine, a scientist in the McEwen Centre for Regenerative Medicine and a senior scientist at the Krembil Research Institute.
5. The director of the University of Toronto Neuroscience Program, Dr. Fehlings is also the co-director of the University of Toronto Spine Program and Krembil Chair in Neural Repair and Regeneration.
6. He has authored more than 725 peer-reviewed articles, many on the topic of SCI and complex spinal surgery.
7. Dr. Fehlings also serves as the site’s principal investigator for InVivo’s INSPIRE study.
More articles on devices:
DePuy Synthes launches new arthroscopic solutions — 4 observations
DePuy Synthes launches ATTUNE Revision Fixed Bearing Tibial Base and Cemented Stem — 5 notes
ATTUNE Knee saves money and increases value — 5 takeaways